Hepatitis C Information - PR Newswire: Schering-Plough's Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity as Monothera

PR Newswire: Schering-Plough's Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity as Monothera
Belga Direct Press Releases - HCV genotype 1 is the most commonform of the virus worldwide and is considered the most difficult to treatsuccessfully. representing an area of great unmetmedical need. Chronic hepatitis C affects more than 10 million people in majorworld

Actilon(TM), Coley Pharmaceutical Group's Drug Candidate For Hepatitis C, Demonstrates Anti-Viral Activity In
BioSpace - as well as long-term control of chronic Hepatitis C. Clinical results to date justify longer-term Phase Ib randomized clinical trial of Actilon in chronic Hepatitis C patients